^
    Back
    Association details:
    Biomarker:EML4-ALK rearrangement
    Cancer:Lung Adenocarcinoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    BMJ Case Rep
    Title:

    EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib

    Published date:
    04/27/2021
    Excerpt:
    A right lower lobectomy based on a diagnosis of lung adenocarcinoma was performed on a 77-year-old Japanese woman…and the mass was diagnosed as metastatic adenocarcinoma harbouring EML4-ALK rearrangement….After starting treatment with lorlatinib, the gastrocnemius tumour diminished and has maintained a stable condition.
    DOI:
    10.1136/bcr-2020-240295